Vanda Pharmaceuticals Inc. (VNDA), Monday announced that the company has submitted a Biologics License Application or BLA to the U.S. Food and Drug Administration for imsidolimab to treat generalized pustular psoriasis, a rare, chronic autoinflammatory skin disorder.
The application is backed by positive results from the global Phase 3 GEMINI-1 and GEMINI-2 studies, which demonstrated that a single intravenous dose of imsidolimab led to rapid disease clearance.
Moreover, the biopharmaceutical company has requested a priority review for the BLA. If granted, the priority review would establish a six-month review cycle, with a potential FDA approval of imsidolimab as early as mid-2026.
CEO Mihael Polymeropoulos commented, "We look forward to potential FDA approval and leveraging our commercial infrastructure to address this debilitating condition."
In the pre-market hours, VNDA is trading at $6.61, up 6.10 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.